Diagnostics Startups funded by Y Combinator (YC) in the San Francisco Bay Area 2024

Notable Labs is building a personalized drug discovery platform to identify treatment options for relapsed and refractory cancer patients — starting with blood cancer — to address the long tail of cancer treatment. We look at a person’s actual cancer cells, test combinations of FDA approved drugs, and see which combinations kill the cancer cells and leave the healthy cells alive. We focus on combinations because cancer is often difficult to target with just one drug and starting with a single drug can lead to resistant clones or relapse. We're building a highly automated lab in Foster City running on our custom software and are currently testing relapsed/refractory cancer patients as well as samples from a variety of pharma/biotech partnerships. https://www.notablelabs.com/careers

Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health. We produce inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world.

BillionToOne has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold, which unlocks transformative improvements in prenatal screening and liquid biopsy for cancers. Unity Screen, BillionToOne's commercially available non-invasive prenatal test (NIPT), is the only NIPT that can assess fetal risk for both recessive conditions and aneuploidies from maternal blood. UNITY Screen continues to grow exponentially and is on its path to becoming the next standard-of-care, with an increasing number of publications showing its accuracy and advantages over other screening methods. We have also recently used our molecular counting technology to develop liquid biopsy tests, which have the potential to completely transform oncology care.

Novel quantitative virtual microscopy for early detection of Alzheimer's disease from non-invasive MRI.

Rev Genomics is a plant biotechnology company that provides breeders, growers, and retailers with novel cultivars to differentiate themselves in high value markets.

Correlia Biosystems is a UC Berkeley spinoff company based in Berkeley, CA. Correlia develops innovative microscale tools that accelerate rapid quantification of biomolecules. Our versatile "SimpleScan" technology opens up new biological questions from one microliter of sample, with rapid results that allow for dynamic monitoring of protein expression profiles (rather than simple end-point measurement). Applications range from enabling next-gen proteomic data sets to point-of-care diagnostics.

We are developing utility-scale molecular sensing using gamified citizen science and a unique, toy-like R&D device.

We quantify brain health and align patients with the right treatment

We provide high quality data for AI radiology. We're building the biggest database of labeled medical data in the world, starting with radiology images. We sell to medical companies who are training and validating AI algorithms.

Leveraging AI to provide veterinarians with more accurate and affordable diagnostics.

Digital health holds a lot of potential but is ignoring a growing problem: diagnostic testing. Without this data, providers and organizations will be limited in the services they can provide patients at home. Scout has developed a platform - Hub, test kits, and app - that delivers health testing at home with 10x lower development cost and 3x lower per-test price. Our patented tech also meets performance requirements for medical diagnoses and integrates with the current healthcare tech stack. Scout’s technology is poised to disrupt the outdated $33Bn diagnostic market by democratizing testing while dramatically improving the patient experience. Scout has received $16M in non-dilutive funding from the NIH and other organizations to fully de-risk our platform, and our pipeline includes a diverse test menu for primary care (e.g. respiratory and sexual health), wellness (e.g. gut health), and chronic conditions (e.g. certain cancers). We have already received FDA authorization for our platform in clinical settings and are planning to launch our flagship Scout Hub in Q1 2024.

Scanbase makes it easy for medical companies to convert photos of rapid diagnostic tests into results. We do this by providing a simple API that any medical company can access.

Over 80% of maternal mortalities were preventable with earlier intervention. Currently, doctors miss >50% of moms who have life-threatening complications and wait until labor to start doing manual risk assessments, at which point it's too late. Elythea's proprietary ML models catch life-threatening obstetric complications (like postpartum hemorrhage, preeclampsia/eclampsia, emergency c-section, preterm labor, and more) as soon as the first visit. We automatically analyze relevant demographic and clinical risk factors, flag high-risk patients, and provide evidence-based interventions, giving doctors months in advance to intervene and prevent complications from ever happening. Our global clinical studies have shown that we can catch 2-3x more complications than clinical judgment 10x sooner.

Loop Genomics provides long-read sequencing solutions across a diverse set of research and clinical applications. Our platform for long-read DNA sequencing transforms short-read DNA sequencers into long-read sequencing machines.

Luminist developed a non-invasive diagnostic test for the early detection and staging of liver fibrosis and non-alcoholic steatohepatitis (NASH). Luminist was acquired in 2020 by DiscernDx.